Pfizer trimmed a handful of programs from its pipeline Wednesday morning as part of its first-quarter earnings update.
The company discontinued development of VTX-801, a recombinant AAV gene therapy for the rare inherited disorder Wilson’s disease that was being developed with Vivet Therapeutics. Pfizer had acquired a minority stake in Vivet in March 2019 and was manufacturing the therapy’s vector for a Phase 1/2 study.
In addition, Pfizer scrapped two potential new indications for its ulcerative colitis drug Velsipity (etrasimod) in atopic dermatitis and alopecia areata, as well as a migraine prevention program for oral Zavzpret (zavegepant). All three had reached Phase 2.
Overall, Pfizer’s development pipeline grew by a net of one program from 112 to 113 over the past three months. On top of the four cuts, Pfizer added or advanced 10 programs to its pipeline and received five approvals across the US and EU.
Total revenues were $14.9 billion for the quarter, down 20% from the first quarter of 2023. Excluding Covid-19 vaccines and Paxlovid, revenues were $12.5 billion (up 11%).